Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 19/20 | 0.69 |
| ▸ | MAOB | P27338 | 8/20 | 0.69 |
| ▸ | MAOA | P21397 | 3/20 | 0.65 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.65 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.65 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25069889 | 1.00 | KDM1A (0.69) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL900481 | 0.83 | KDM1A (0.72) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL19409816 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL18214503 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL16021069 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL14880428 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL19422223 | 0.82 | KDM1A (0.76) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL14880427 | 0.82 | KDM1A (1.00) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL23162761 | 0.82 | KDM1A (0.66) | KDM1AMAOBMAOAKDM1BRCOR1 | |
| SCHEMBL900351 | 0.82 | KDM1A (0.70) | KDM1AMAOBMAOAKDM1BRCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | KDM1A 2576/4885MAOB 4262/4885MAOA 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.